595 related articles for article (PubMed ID: 17620745)
1. The economics of effective AIDS treatment in Thailand.
Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
[TBL] [Abstract][Full Text] [Related]
2. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
Marseille E; Saba J; Muyingo S; Kahn JG
AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
[TBL] [Abstract][Full Text] [Related]
3. The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand.
Chasombat S; Lertpiriyasuwat C; Thanprasertsuk S; Suebsaeng L; Lo YR
Southeast Asian J Trop Med Public Health; 2006 Jul; 37(4):704-15. PubMed ID: 17121296
[TBL] [Abstract][Full Text] [Related]
4. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
Beck EJ; Mandalia S; Youle M; Brettle R; Fisher M; Gompels M; Kinghorn G; McCarron B; Pozniak A; Tang A; Walsh J; Williams I; Gazzard B
Int J STD AIDS; 2008 May; 19(5):297-304. PubMed ID: 18482958
[TBL] [Abstract][Full Text] [Related]
7. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
[TBL] [Abstract][Full Text] [Related]
8. Assessing efficiency and costs of scaling up HIV treatment.
Cleary SM; McIntyre D; Boulle AM
AIDS; 2008 Jul; 22 Suppl 1():S35-42. PubMed ID: 18664951
[TBL] [Abstract][Full Text] [Related]
9. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
Quentin W; König HH; Schmidt JO; Kalk A
Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options.
Over M; Marseille E; Sudhakar K; Gold J; Gupta I; Indrayan A; Hira S; Nagelkerke N; Rao AS; Heywood P
Sex Transm Dis; 2006 Oct; 33(10 Suppl):S145-52. PubMed ID: 17003679
[TBL] [Abstract][Full Text] [Related]
11. Combining prevention, treatment and care: lessons from South Africa.
Achmat Z; Simcock J
AIDS; 2007 Jul; 21 Suppl 4():S11-20. PubMed ID: 17620746
[TBL] [Abstract][Full Text] [Related]
12. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
Simpson KN; Baran RW; Kirbach SE; Dietz B
Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
[TBL] [Abstract][Full Text] [Related]
13. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine.
Biddle AK; Simpson KN
Value Health; 2000; 3(3):186-201. PubMed ID: 16464183
[TBL] [Abstract][Full Text] [Related]
14. Costs associated with combination antiretroviral therapy in HIV-infected patients.
Yazdanpanah Y
J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
[TBL] [Abstract][Full Text] [Related]
15. The (political) economics of antiretroviral treatment in developing countries.
Nattrass NJ
Trends Microbiol; 2008 Dec; 16(12):574-9. PubMed ID: 18964022
[TBL] [Abstract][Full Text] [Related]
16. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.
Renaud-Théry F; Nguimfack BD; Vitoria M; Lee E; Graaff P; Samb B; Perriëns J
AIDS; 2007 Jul; 21 Suppl 4():S89-95. PubMed ID: 17620758
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
18. Providing antiretroviral therapy for HIV infection.
Steinbrook R
N Engl J Med; 2001 Mar; 344(11):844-6. PubMed ID: 11248164
[No Abstract] [Full Text] [Related]
19. [Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
Blasco AJ; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Llibre JM; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):283-93. PubMed ID: 22525829
[TBL] [Abstract][Full Text] [Related]
20. The affordability of antiretroviral therapy in developing countries: what policymakers need to know.
Forsythe SS
AIDS; 1998; 12 Suppl 2():S11-8. PubMed ID: 9792357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
